Skip to main content
Erschienen in: European Spine Journal 12/2023

23.10.2023 | Original Article

Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?

verfasst von: Xianglin Hu, Tomohiro Fujiwara, Yangbai Sun, Wending Huang, Wangjun Yan

Erschienen in: European Spine Journal | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent studies demonstrated that primary tumor resection (PTR) improves survival of patients with metastatic bone sarcomas. However, it remains quite unclear regarding the role of PTR in the treatment of sarcomas of pelvic bones with synchronous metastasis at diagnosis.

Methods

Using the Surveillance, Epidemiology, and End Results Program, we enrolled a total of 385 patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at initial diagnosis, including 139 patients with osteosarcoma, 176 with Ewing sarcoma, and 70 with chondrosarcoma. Association between PTR and disease-specific survival (DSS) were investigated using the univariable and multivariable Cox regression models. Hazard ratio (HR) and 95% confidence interval (CI) were reported. Representative institutional PTR strategies and clinical outcomes for patients with metastatic pelvic sarcomas from our cancer center were displayed.

Results

The usage rate of PTR was 28.1% (39/139) in osteosarcoma, 13.6% (24/176) in Ewing sarcoma, and 41.4% (29/70) in chondrosarcoma with synchronous metastatic lesions. PTR was not associated with an improved DSS for metastatic pelvic osteosarcoma (HR = 0.686, 95% CI = 0.430 ~ 1.094, P = 0.113) and Ewing sarcoma (HR = 0.580, 95% CI = 0.291 ~ 1.154, P = 0.121). The use of PTR was associated with an improved DSS for metastatic pelvic chondrosarcoma (HR = 0.464, 95% CI = 0.225 ~ 0.954, P = 0.037).

Conclusion

Primary lesion resection may provide a survival benefit for metastatic chondrosarcoma, but not for osteosarcoma and Ewing sarcoma of pelvic bones, sacrum, and coccyx. This population-based study recommends an active surgical intervention for metastatic chondrosarcoma while non-surgical treatment for metastatic osteosarcoma and Ewing sarcoma of the pelvis in terms of survival improvement.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Hu X, Deng K, Ye H, Sun Z, Huang W, Sun Y, Yan W (2021) Trends in tumor site-specific survival of bone sarcomas from 1980 to 2018: a surveillance, epidemiology and end results-based study. Cancers (Basel) 13(21):5381CrossRefPubMed Hu X, Deng K, Ye H, Sun Z, Huang W, Sun Y, Yan W (2021) Trends in tumor site-specific survival of bone sarcomas from 1980 to 2018: a surveillance, epidemiology and end results-based study. Cancers (Basel) 13(21):5381CrossRefPubMed
3.
Zurück zum Zitat Meazza C, Scanagatta P (2016) Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 16(5):543–556CrossRefPubMed Meazza C, Scanagatta P (2016) Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 16(5):543–556CrossRefPubMed
4.
Zurück zum Zitat Tsukamoto S, Errani C, Angelini A, Mavrogenis AF (2020) Current treatment considerations for osteosarcoma metastatic at presentation. Orthopedics 43(5):e345–e358CrossRefPubMed Tsukamoto S, Errani C, Angelini A, Mavrogenis AF (2020) Current treatment considerations for osteosarcoma metastatic at presentation. Orthopedics 43(5):e345–e358CrossRefPubMed
5.
Zurück zum Zitat Malik AT, Alexander JH, Mayerson JL, Khan SN, Scharschmidt TJ (2020) Is surgical resection of the primary site associated with an improved overall survival for patients with primary malignant bone tumors who have metastatic disease at presentation? Clin Orthop Relat Res 478(10):2284–2295CrossRefPubMedPubMedCentral Malik AT, Alexander JH, Mayerson JL, Khan SN, Scharschmidt TJ (2020) Is surgical resection of the primary site associated with an improved overall survival for patients with primary malignant bone tumors who have metastatic disease at presentation? Clin Orthop Relat Res 478(10):2284–2295CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Song K, Song J, Chen F, Lin K, Ma X, Jiang J (2019) Does resection of the primary tumor improve survival in patients with metastatic chondrosarcoma? Clin Orthop Relat Res 477(3):573–583CrossRefPubMedPubMedCentral Song K, Song J, Chen F, Lin K, Ma X, Jiang J (2019) Does resection of the primary tumor improve survival in patients with metastatic chondrosarcoma? Clin Orthop Relat Res 477(3):573–583CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Zhang L, Akiyama T, Fukushima T, Iwata S, Takeshita K, Kawai A, Tanaka S, Kobayashi H (2021) Surgical resection of the primary lesion for osteosarcoma patients with metastasis at initial diagnosis. Jpn J Clin Oncol 51(3):416–423CrossRefPubMed Zhang L, Akiyama T, Fukushima T, Iwata S, Takeshita K, Kawai A, Tanaka S, Kobayashi H (2021) Surgical resection of the primary lesion for osteosarcoma patients with metastasis at initial diagnosis. Jpn J Clin Oncol 51(3):416–423CrossRefPubMed
8.
Zurück zum Zitat Ren Y, Zhang Z, Shang L, You X (2019) Surgical resection of primary ewing’s sarcoma of bone improves overall survival in patients presenting with metastasis. Med Sci Monit 16(25):1254–1262CrossRef Ren Y, Zhang Z, Shang L, You X (2019) Surgical resection of primary ewing’s sarcoma of bone improves overall survival in patients presenting with metastasis. Med Sci Monit 16(25):1254–1262CrossRef
9.
Zurück zum Zitat Minichsdorfer C, Steinbrecher O, KÖlz M, Schmid M, Raderer M, Brodowicz T, Lamm W (2021) Adolescents and young adults (ayas) with initially localized and metastatic bone sarcomas: a retrospective single center analysis of side effect management. In Vivo 35(1):385–391CrossRefPubMedPubMedCentral Minichsdorfer C, Steinbrecher O, KÖlz M, Schmid M, Raderer M, Brodowicz T, Lamm W (2021) Adolescents and young adults (ayas) with initially localized and metastatic bone sarcomas: a retrospective single center analysis of side effect management. In Vivo 35(1):385–391CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Brady SW, Ma X, Bahrami A, Satas G, Wu G, Newman S, Rusch M, Putnam DK, Mulder HL, Yergeau DA, Edmonson MN, Easton J, Alexandrov LB, Chen X, Mardis ER, Wilson RK, Downing JR, Pappo AS, Raphael BJ, Dyer MA, Zhang J (2019) The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment. Mol Cancer Res 17(4):895–906CrossRefPubMedPubMedCentral Brady SW, Ma X, Bahrami A, Satas G, Wu G, Newman S, Rusch M, Putnam DK, Mulder HL, Yergeau DA, Edmonson MN, Easton J, Alexandrov LB, Chen X, Mardis ER, Wilson RK, Downing JR, Pappo AS, Raphael BJ, Dyer MA, Zhang J (2019) The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment. Mol Cancer Res 17(4):895–906CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Lyu HG, Haider AH, Landman AB, Raut CP (2019) The opportunities and shortcomings of using big data and national databases for sarcoma research. Cancer 125(17):2926–2934CrossRefPubMed Lyu HG, Haider AH, Landman AB, Raut CP (2019) The opportunities and shortcomings of using big data and national databases for sarcoma research. Cancer 125(17):2926–2934CrossRefPubMed
13.
Zurück zum Zitat Gallicchio L, Daee DL, Rotunno M, Barajas R, Fagan S, Carrick DM, Divi RL, Filipski KK, Freedman AN, Gillanders EM, Lam TK, Martin DN, Rogers S, Verma M, Nelson SA (2021) Epidemiologic research of rare cancers: trends, resources, and challenges. Cancer Epidemiol Biomark Prev 30(7):1305–1311CrossRef Gallicchio L, Daee DL, Rotunno M, Barajas R, Fagan S, Carrick DM, Divi RL, Filipski KK, Freedman AN, Gillanders EM, Lam TK, Martin DN, Rogers S, Verma M, Nelson SA (2021) Epidemiologic research of rare cancers: trends, resources, and challenges. Cancer Epidemiol Biomark Prev 30(7):1305–1311CrossRef
14.
Zurück zum Zitat Brown JM, Matichak D, Rakoczy K, Groundland J (2021) Osteosarcoma of the pelvis: clinical presentation and overall survival. Sarcoma 6(2021):8027314 Brown JM, Matichak D, Rakoczy K, Groundland J (2021) Osteosarcoma of the pelvis: clinical presentation and overall survival. Sarcoma 6(2021):8027314
15.
Zurück zum Zitat Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F (2022) Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: a retrospective series of the French sarcoma group. Int J Cancer 150(4):645–653CrossRefPubMed Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F (2022) Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: a retrospective series of the French sarcoma group. Int J Cancer 150(4):645–653CrossRefPubMed
16.
Zurück zum Zitat Odri GA, Tchicaya-Bouanga J, Yoon DJY, Modrowski D (2022) Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers. Cancers (Basel) 14(2):360CrossRefPubMed Odri GA, Tchicaya-Bouanga J, Yoon DJY, Modrowski D (2022) Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers. Cancers (Basel) 14(2):360CrossRefPubMed
17.
Zurück zum Zitat Meazza C, Bastoni S, Scanagatta P (2020) What is the best clinical approach to recurrent/refractory osteosarcoma? Expert Rev Anticancer Ther 20(5):415–428CrossRefPubMed Meazza C, Bastoni S, Scanagatta P (2020) What is the best clinical approach to recurrent/refractory osteosarcoma? Expert Rev Anticancer Ther 20(5):415–428CrossRefPubMed
18.
Zurück zum Zitat Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J (2020) Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev 86:101993CrossRefPubMed Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J (2020) Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev 86:101993CrossRefPubMed
19.
Zurück zum Zitat Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY (2019) Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20(1):120–133CrossRefPubMed Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY (2019) Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20(1):120–133CrossRefPubMed
20.
Zurück zum Zitat Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG (2019) Randomized double-blind phase ii study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol 37(16):1424–1431CrossRefPubMedPubMedCentral Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG (2019) Randomized double-blind phase ii study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol 37(16):1424–1431CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Duffaud F (2020) Role of TKI for metastatic osteogenic sarcoma. Curr Treat Options Oncol 21(8):65CrossRefPubMed Duffaud F (2020) Role of TKI for metastatic osteogenic sarcoma. Curr Treat Options Oncol 21(8):65CrossRefPubMed
22.
Zurück zum Zitat Worch J, Ranft A, DuBois SG, Paulussen M, Juergens H, Dirksen U (2018) Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. Pediatr Blood Cancer 65(9):e27251CrossRefPubMed Worch J, Ranft A, DuBois SG, Paulussen M, Juergens H, Dirksen U (2018) Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. Pediatr Blood Cancer 65(9):e27251CrossRefPubMed
23.
Zurück zum Zitat Jagodzińska-Mucha P, Raciborska A, Koseła-Paterczyk H, Kozak K, Bilska K, Świtaj T, Falkowski S, Dawidowska A, Rutkowski P, Ługowska I (2021) Age as a prognostic factor in patients with ewing sarcoma-the polish sarcoma group experience. J Clin Med 10(16):3627CrossRefPubMedPubMedCentral Jagodzińska-Mucha P, Raciborska A, Koseła-Paterczyk H, Kozak K, Bilska K, Świtaj T, Falkowski S, Dawidowska A, Rutkowski P, Ługowska I (2021) Age as a prognostic factor in patients with ewing sarcoma-the polish sarcoma group experience. J Clin Med 10(16):3627CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Bosma SE, van der Heijden L, Sierrasesúmaga L, Merks HJHM, Haveman LM, van de Sande MAJ, San-Julián M (2022) What do we know about survival in skeletally premature children aged 0 to 10 years with ewing sarcoma? a multicenter 10-year follow-up study in 60 patients. Cancers (Basel) 14(6):1456CrossRefPubMed Bosma SE, van der Heijden L, Sierrasesúmaga L, Merks HJHM, Haveman LM, van de Sande MAJ, San-Julián M (2022) What do we know about survival in skeletally premature children aged 0 to 10 years with ewing sarcoma? a multicenter 10-year follow-up study in 60 patients. Cancers (Basel) 14(6):1456CrossRefPubMed
25.
Zurück zum Zitat Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY (2020) Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21(3):446–455CrossRefPubMedPubMedCentral Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY (2020) Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21(3):446–455CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Fagioli F, Tirtei E (2020) Cabozantinib: a new perspective for advanced bone sarcoma. Lancet Oncol 21(3):331–332CrossRefPubMed Fagioli F, Tirtei E (2020) Cabozantinib: a new perspective for advanced bone sarcoma. Lancet Oncol 21(3):331–332CrossRefPubMed
Metadaten
Titel
Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?
verfasst von
Xianglin Hu
Tomohiro Fujiwara
Yangbai Sun
Wending Huang
Wangjun Yan
Publikationsdatum
23.10.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Spine Journal / Ausgabe 12/2023
Print ISSN: 0940-6719
Elektronische ISSN: 1432-0932
DOI
https://doi.org/10.1007/s00586-023-07985-x

Weitere Artikel der Ausgabe 12/2023

European Spine Journal 12/2023 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Knie-TEP: Kein Vorteil durch antibiotikahaltigen Knochenzement

29.05.2024 Periprothetische Infektionen Nachrichten

Zur Zementierung einer Knie-TEP wird in Deutschland zu über 98% Knochenzement verwendet, der mit einem Antibiotikum beladen ist. Ob er wirklich besser ist als Zement ohne Antibiotikum, kann laut Registerdaten bezweifelt werden.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.